Salivary Metabolomics Found 65 Cannabis-Responsive Biomarkers in Children With Autism Treated With Medical Cannabis
Using metabolomics analysis of saliva from 15 ASD children on individualized medical cannabis, 65 potential biomarkers shifted toward typically developing levels, including markers linked to inflammation, neurotransmitters, and endocannabinoids.
Quick Facts
What This Study Found
65 potential cannabis-responsive biomarkers shifted toward TD physiological levels in ASD children after medical cannabis treatment. 23 were categorized as anti-inflammatory, bioenergy-associated, neurotransmitters, amino acids, and endocannabinoids. N-acetylaspartic acid, spermine, and dehydroisoandrosterone 3-sulfate changes were particularly notable as they have been previously linked to ASD behavioral symptoms.
Key Numbers
N=15 ASD, N=9 TD. 65 cannabis-responsive biomarkers. 23 characterized in detail. 40% THC-dominant, 60% CBD-dominant treatment. THC: 0.05-50mg, CBD: 7.5-200mg per dose.
How They Did This
Observational pharmacometabolomics study of saliva from 15 ASD children (pre-treatment and at maximal impact) compared with 9 TD controls. 40% received THC-dominant MC, 60% received CBD-dominant MC. Individualized regimens for 1+ year.
Why This Research Matters
Developing objective biomarkers for ASD treatment response has been a longstanding challenge. This metabolomics approach could enable precision dosing and treatment monitoring rather than relying solely on behavioral observation.
The Bigger Picture
This companion paper to the lipidomics study (RTHC-04937) from the same group adds metabolomics data to build a more complete picture of how cannabis affects ASD biology at the molecular level. The convergence of both approaches strengthens the biomarker concept.
What This Study Doesn't Tell Us
Very small sample without placebo control. Individualized treatment prevents standardized comparison. Biomarker shifts correlate with behavioral improvement but cannot prove causation. Observational design. Results need replication in larger trials.
Questions This Raises
- ?Could these biomarkers be validated in a placebo-controlled ASD cannabis trial?
- ?Do THC-dominant and CBD-dominant treatments produce different biomarker profiles?
Trust & Context
- Key Stat:
- 65 salivary metabolite biomarkers responded to cannabis treatment in ASD children
- Evidence Grade:
- Small observational study establishing biomarker discovery. Requires validation in larger controlled trials.
- Study Age:
- Published in 2023.
- Original Title:
- Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.
- Published In:
- Cannabis and cannabinoid research, 8(1), 126-137 (2023)
- Authors:
- Siani-Rose, Michael(3), Cox, Stephany(2), Goldstein, Bonni(3), Abrams, Donald, Taylor, Myiesha, Kurek, Itzhak
- Database ID:
- RTHC-04938
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can saliva metabolomics track cannabis treatment for autism?
This preliminary study identified 65 metabolite biomarkers that shifted toward typical levels in ASD children on medical cannabis, suggesting saliva could be used for objective treatment monitoring.
Which biomarkers changed most in ASD children on cannabis?
N-acetylaspartic acid, spermine, and dehydroisoandrosterone 3-sulfate were highlighted because they have been previously linked to ASD behavioral symptoms.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04938APA
Siani-Rose, Michael; Cox, Stephany; Goldstein, Bonni; Abrams, Donald; Taylor, Myiesha; Kurek, Itzhak. (2023). Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.. Cannabis and cannabinoid research, 8(1), 126-137. https://doi.org/10.1089/can.2021.0129
MLA
Siani-Rose, Michael, et al. "Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.." Cannabis and cannabinoid research, 2023. https://doi.org/10.1089/can.2021.0129
RethinkTHC
RethinkTHC Research Database. "Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based..." RTHC-04938. Retrieved from https://rethinkthc.com/research/siani-rose-2023-cannabisresponsive-biomarkers-a-pharmacometabolomicsbased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.